Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Here's What You Missed in Cannabis This Week » 11:49
06/23/22
06/23
11:49
06/23/22
11:49
SNDL

Sundial Growers

/

+

, HEXO

Hexo

/

+

, CRON

Cronos Group

$2.88 /

+0.1 (+3.60%)

, DNA

Ginkgo Bioworks

$2.78 /

+0.295 (+11.87%)

, BMMJ

Body and Mind

/

+

, AUSAF

Australis Capital

/

+

, VLNS

Valens

/

+

, ACB

Aurora Cannabis

$1.36 /

+0.065 (+5.04%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.47 /

+0.12 (+3.58%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.47 /

+0.03 (+2.08%)

, GTBIF

Green Thumb Industries

$8.75 /

-0.01 (-0.11%)

, IGC

India Globalization Capital

/

+

, TLRY

Tilray

$3.33 /

+0.11 (+3.42%)

, TCNNF

Trulieve Cannabis

$13.45 /

+0.24 (+1.82%)

, ZYNE

Zynerba

$1.17 /

+0.03 (+2.63%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.17 /

+0.03 (+2.63%)

VLNS Valens
/

+

TLRY Tilray
$3.33 /

+0.11 (+3.42%)

TCNNF Trulieve Cannabis
$13.45 /

+0.24 (+1.82%)

SNDL Sundial Growers
/

+

IGC India Globalization Capital
/

+

HEXO Hexo
/

+

GTBIF Green Thumb Industries
$8.75 /

-0.01 (-0.11%)

GDNSF Goodness Growth
$1.47 /

+0.03 (+2.08%)

DNA Ginkgo Bioworks
$2.78 /

+0.295 (+11.87%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$2.88 /

+0.1 (+3.60%)

CGC Canopy Growth
$3.47 /

+0.12 (+3.58%)

AUSAF Australis Capital
/

+

ACB Aurora Cannabis
$1.36 /

+0.065 (+5.04%)

SNDL Sundial Growers
/

+

05/03/22 BMO Capital
Sundial Growers upgraded to Market Perform from Underperform at BMO Capital
05/03/22 BMO Capital
Sundial Growers upgraded to Market Perform from Underperform at BMO Capital
07/20/21 ATB Capital
Sundial Growers upgraded to Sector Perform from Underperform at ATB Capital
HEXO Hexo
/

+

06/16/22 Canaccord
Hexo downgraded to Hold at Canaccord on faltering turnaround prospects
06/15/22 Canaccord
Hexo downgraded to Hold from Speculative Buy at Canaccord
06/15/22 Alliance Global Partners
Hexo downgraded to Neutral from Buy at Alliance Global Partners
06/15/22 Canaccord
Tilray price target lowered to $7 from $9 at CanaccordHexo
CRON Cronos Group
$2.88 /

+0.1 (+3.60%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
DNA Ginkgo Bioworks
$2.78 /

+0.295 (+11.87%)

06/16/22 Jefferies
Ginkgo Bioworks price target lowered to $4.35 from $11.50 at Jefferies
05/18/22 BofA
BofA downgrades Ginkgo Bioworks to Underperform, halves target to $3
05/18/22 BofA
Ginkgo Bioworks downgraded to Underperform from Neutral at BofA
03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
BMMJ Body and Mind
/

+

AUSAF Australis Capital
/

+

VLNS Valens
/

+

04/18/22 Stifel
Valens price target lowered to C$4.50 from C$5.25 at Stifel
03/02/22 Raymond James
Valens downgraded to Underperform from Market Perform at Raymond James
03/02/22 Canaccord
Valens price target lowered to C$7 from C$9 at Canaccord
02/14/22 Raymond James
Valens price target lowered to C$5 from C$7.50 at Raymond James
ACB Aurora Cannabis
$1.36 /

+0.065 (+5.04%)

06/24/22 Cantor Fitzgerald
Cantor upgrades Aurora to Overweight on potential catalyst in Germany
06/24/22 Cantor Fitzgerald
Aurora Cannabis upgraded to Overweight from Neutral at Cantor Fitzgerald
06/06/22 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
CVSI CV Sciences
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CGC Canopy Growth
$3.47 /

+0.12 (+3.58%)

06/08/22 BMO Capital
Canopy Growth downgraded to Underperform from Market Perform at BMO Capital
06/08/22 Barclays
Canopy Growth price target lowered to $3.50 from $6 at Barclays
05/31/22 Canaccord
Canopy Growth price target lowered to C$4.50 from C$6 at Canaccord
05/31/22 CIBC
Canopy Growth price target lowered to C$5 from C$6.50 at CIBC
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.47 /

+0.03 (+2.08%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$8.75 /

-0.01 (-0.11%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
IGC India Globalization Capital
/

+

TLRY Tilray
$3.33 /

+0.11 (+3.42%)

TCNNF Trulieve Cannabis
$13.45 /

+0.24 (+1.82%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
ZYNE Zynerba
$1.17 /

+0.03 (+2.63%)

06/23/22 Canaccord
Zynerba price target raised to $11 from $9 at Canaccord
ZYNE Zynerba
$1.17 /

+0.03 (+2.63%)

VLNS Valens
/

+

TLRY Tilray
$3.33 /

+0.11 (+3.42%)

TCNNF Trulieve Cannabis
$13.45 /

+0.24 (+1.82%)

HEXO Hexo
/

+

GTBIF Green Thumb Industries
$8.75 /

-0.01 (-0.11%)

DNA Ginkgo Bioworks
$2.78 /

+0.295 (+11.87%)

CVSI CV Sciences
/

+

CRON Cronos Group
$2.88 /

+0.1 (+3.60%)

CGC Canopy Growth
$3.47 /

+0.12 (+3.58%)

ACB Aurora Cannabis
$1.36 /

+0.065 (+5.04%)

  • 27
    May
  • 20
    Aug
CRON Cronos Group
$2.88 /

+0.1 (+3.60%)

VLNS Valens
/

+

SNDL Sundial Growers
/

+

HEXO Hexo
/

+

DNA Ginkgo Bioworks
$2.78 /

+0.295 (+11.87%)

CRON Cronos Group
$2.88 /

+0.1 (+3.60%)

CGC Canopy Growth
$3.47 /

+0.12 (+3.58%)

BMMJ Body and Mind
/

+

ACB Aurora Cannabis
$1.36 /

+0.065 (+5.04%)

TLRY Tilray
$3.33 /

+0.11 (+3.42%)

SNDL Sundial Growers
/

+

HEXO Hexo
/

+

DNA Ginkgo Bioworks
$2.78 /

+0.295 (+11.87%)

CGC Canopy Growth
$3.47 /

+0.12 (+3.58%)

ACB Aurora Cannabis
$1.36 /

+0.065 (+5.04%)

Recommendations
Zynerba price target raised to $11 from $9 at Canaccord » 07:44
06/23/22
06/23
07:44
06/23/22
07:44
ZYNE

Zynerba

$1.14 /

+0.035 (+3.17%)

Canaccord analyst Sumant…

Canaccord analyst Sumant Kulkarni raised the firm's price target on Zynerba to $11 from $9 and keeps a Buy rating on the shares. The analyst believes the shares remain significantly undervalued if they are successful on executing its plans for Zygel, Kulkarni said based on INSPIRE data, he raised hisprobability of approval assumption for Zygel in 2022 from 15% to 33%.

ShowHide Related Items >><<
ZYNE Zynerba
$1.14 /

+0.035 (+3.17%)

ZYNE Zynerba
$1.14 /

+0.035 (+3.17%)

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
ZYNE Zynerba
$1.14 /

+0.035 (+3.17%)

ZYNE Zynerba
$1.14 /

+0.035 (+3.17%)

ZYNE Zynerba
$1.14 /

+0.035 (+3.17%)

Tuesday
Hot Stocks
Zynerba announces positive top line results from phase 2 trial of Zygel » 20:54
06/21/22
06/21
20:54
06/21/22
20:54
ZYNE

Zynerba

$1.11 /

-0.005 (-0.45%)

Zynerba "announced…

Zynerba "announced positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the Company will request a meeting with the FDA to discuss the data and the regulatory path forward. The 14-week INSPIRE trial was an open-label, Phase 2 clinical trial designed to evaluate the safety, tolerability and efficacy of Zygel in children and adolescents with genetically-confirmed 22q11.2 deletion syndrome. Enrolled patients received weight-based doses of 250 mg or 500 mg daily of Zygel. Patients were allowed to increase the daily dose after six weeks of treatment to 500 mg and 750 mg if the investigator felt such increase was appropriate. One patient's dose was increased from 250 mg to 500 mg, and no patients increased to 750 mg in the treatment period. At the completion of the trial, thirteen patients entered into an extension study for up to six months." CEO Armando Anido states: "We believe the data from this Phase 2 trial are very encouraging and reinforce the potential of Zygel for the treatment of behavioral symptoms in children and adolescents with 22q, and we look forward to discussing the regulatory path forward with the FDA with these data in hand. In the near term, we will focus our resources on completing the RECONNECT trial for children and adolescents with Fragile X syndrome and progressing 22q."

ShowHide Related Items >><<
ZYNE Zynerba
$1.11 /

-0.005 (-0.45%)

ZYNE Zynerba
$1.11 /

-0.005 (-0.45%)

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
ZYNE Zynerba
$1.11 /

-0.005 (-0.45%)

ZYNE Zynerba
$1.11 /

-0.005 (-0.45%)

ZYNE Zynerba
$1.11 /

-0.005 (-0.45%)

Over a week ago
On The Fly
Here's What You Missed in Cannabis This Week » 11:59
06/16/22
06/16
11:59
06/16/22
11:59
FFLWF

Fire & Flower Holdings

$2.26 /

+0.1409 (+6.65%)

, HITI

High Tide

$2.00 /

-0.04 (-1.96%)

, HEXO

Hexo

/

+

, CNPOF

RIV Capital

/

+

, TLRY

Tilray

$3.10 /

-0.105 (-3.28%)

, AYRWF

Ayr Wellness

$5.38 /

+ (+0.00%)

, IIPR

Innovative Industrial Properties

$111.97 /

-4.46 (-3.83%)

, VLNS

Valens

/

+

, ACB

Aurora Cannabis

$1.27 /

-0.07 (-5.24%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.32 /

-0.205 (-5.82%)

, CRON

Cronos Group

$2.68 /

-0.045 (-1.65%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.55 /

+0.06 (+4.03%)

, GTBIF

Green Thumb Industries

$9.50 /

+0.095 (+1.01%)

, IGC

India Globalization Capital

/

+

, TCNNF

Trulieve Cannabis

$13.65 /

+0.45 (+3.41%)

, ZYNE

Zynerba

$1.07 /

-0.06 (-5.31%)

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
$1.07 /

-0.06 (-5.31%)

VLNS Valens
/

+

TLRY Tilray
$3.10 /

-0.105 (-3.28%)

TCNNF Trulieve Cannabis
$13.65 /

+0.45 (+3.41%)

IIPR Innovative Industrial Properties
$111.97 /

-4.46 (-3.83%)

HITI High Tide
$2.00 /

-0.04 (-1.96%)

HEXO Hexo
/

+

GTBIF Green Thumb Industries
$9.50 /

+0.095 (+1.01%)

GDNSF Goodness Growth
$1.55 /

+0.06 (+4.03%)

FFLWF Fire & Flower Holdings
$2.26 /

+0.1409 (+6.65%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$2.68 /

-0.045 (-1.65%)

CGC Canopy Growth
$3.32 /

-0.205 (-5.82%)

AYRWF Ayr Wellness
$5.38 /

+ (+0.00%)

ACB Aurora Cannabis
$1.27 /

-0.07 (-5.24%)

FFLWF Fire & Flower Holdings
$2.26 /

+0.1409 (+6.65%)

06/15/22 Stifel
Fire & Flower Holdings price target lowered to C$5.50 from C$8.50 at Stifel
04/28/22 Stifel
Fire & Flower Holdings price target lowered to C$8.50 from C$12 at Stifel
12/15/21 Stifel
Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel
11/23/21 Cantor Fitzgerald
Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald
HITI High Tide
$2.00 /

-0.04 (-1.96%)

01/31/22 Desjardins
High Tide price target lowered to C$11.50 from C$13.50 at Desjardins
11/22/21 Cantor Fitzgerald
High Tide initiated with a Neutral at Cantor Fitzgerald
10/22/21 Desjardins
High Tide price target lowered to C$13.50 from C$15 at Desjardins
10/07/21 Roth Capital
Roth Capital views High Tide acquisition of Blessed CBD 'favorably'
HEXO Hexo
/

+

06/16/22 Canaccord
Hexo downgraded to Hold at Canaccord on faltering turnaround prospects
06/15/22 Canaccord
Hexo downgraded to Hold from Speculative Buy at Canaccord
06/15/22 Alliance Global Partners
Hexo downgraded to Neutral from Buy at Alliance Global Partners
06/15/22 Canaccord
Tilray price target lowered to $7 from $9 at CanaccordHexo
CNPOF RIV Capital
/

+

09/23/21 CIBC
RIV Capital price target lowered to C$2.25 from C$2.50 at CIBC
TLRY Tilray
$3.10 /

-0.105 (-3.28%)

06/15/22 Piper Sandler
Tilray price target lowered to $3 from $6 at Piper Sandler
AYRWF Ayr Wellness
$5.38 /

+ (+0.00%)

03/18/22 Canaccord
Ayr Wellness price target lowered to C$40 from C$57 at Canaccord
03/03/22 Needham
Ayr Wellness price target lowered to $28 from $35 at Needham
12/20/21 Needham
Ayr Wellness named Cannabis Top Pick for 2022 at Needham
11/23/21 Canaccord
Ayr Wellness price target lowered to C$62 from C$70 at Canaccord
IIPR Innovative Industrial Properties
$111.97 /

-4.46 (-3.83%)

06/02/22 JMP Securities
Innovative Industrial Properties price target lowered to $190 from $300 at JMP Securities
05/09/22 Craig-Hallum
Craig-Hallum upgrades Innovative Industrial Properties to Buy with $175 target
05/09/22 Craig-Hallum
Innovative Industrial Properties upgraded to Buy from Hold at Craig-Hallum
01/14/22 Piper Sandler
Innovative Industrial price target lowered to $285 from $290 at Piper Sandler
VLNS Valens
/

+

04/18/22 Stifel
Valens price target lowered to C$4.50 from C$5.25 at Stifel
03/02/22 Raymond James
Valens downgraded to Underperform from Market Perform at Raymond James
03/02/22 Canaccord
Valens price target lowered to C$7 from C$9 at Canaccord
02/14/22 Raymond James
Valens price target lowered to C$5 from C$7.50 at Raymond James
ACB Aurora Cannabis
$1.27 /

-0.07 (-5.24%)

06/06/22 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
CVSI CV Sciences
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CGC Canopy Growth
$3.32 /

-0.205 (-5.82%)

06/08/22 BMO Capital
Canopy Growth downgraded to Underperform from Market Perform at BMO Capital
06/08/22 Barclays
Canopy Growth price target lowered to $3.50 from $6 at Barclays
05/31/22 Canaccord
Canopy Growth price target lowered to C$4.50 from C$6 at Canaccord
05/31/22 CIBC
Canopy Growth price target lowered to C$5 from C$6.50 at CIBC
CRON Cronos Group
$2.68 /

-0.045 (-1.65%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.55 /

+0.06 (+4.03%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$9.50 /

+0.095 (+1.01%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
IGC India Globalization Capital
/

+

TCNNF Trulieve Cannabis
$13.65 /

+0.45 (+3.41%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
ZYNE Zynerba
$1.07 /

-0.06 (-5.31%)

ZYNE Zynerba
$1.07 /

-0.06 (-5.31%)

VLNS Valens
/

+

TLRY Tilray
$3.10 /

-0.105 (-3.28%)

TCNNF Trulieve Cannabis
$13.65 /

+0.45 (+3.41%)

IIPR Innovative Industrial Properties
$111.97 /

-4.46 (-3.83%)

HITI High Tide
$2.00 /

-0.04 (-1.96%)

HEXO Hexo
/

+

GTBIF Green Thumb Industries
$9.50 /

+0.095 (+1.01%)

CVSI CV Sciences
/

+

CRON Cronos Group
$2.68 /

-0.045 (-1.65%)

CGC Canopy Growth
$3.32 /

-0.205 (-5.82%)

AYRWF Ayr Wellness
$5.38 /

+ (+0.00%)

ACB Aurora Cannabis
$1.27 /

-0.07 (-5.24%)

  • 27
    May
  • 01
    Apr
  • 20
    Aug
TLRY Tilray
$3.10 /

-0.105 (-3.28%)

IIPR Innovative Industrial Properties
$111.97 /

-4.46 (-3.83%)

VLNS Valens
/

+

TLRY Tilray
$3.10 /

-0.105 (-3.28%)

IIPR Innovative Industrial Properties
$111.97 /

-4.46 (-3.83%)

HITI High Tide
$2.00 /

-0.04 (-1.96%)

HEXO Hexo
/

+

FFLWF Fire & Flower Holdings
$2.26 /

+0.1409 (+6.65%)

CGC Canopy Growth
$3.32 /

-0.205 (-5.82%)

AYRWF Ayr Wellness
$5.38 /

+ (+0.00%)

ACB Aurora Cannabis
$1.27 /

-0.07 (-5.24%)

TLRY Tilray
$3.10 /

-0.105 (-3.28%)

HEXO Hexo
/

+

CGC Canopy Growth
$3.32 /

-0.205 (-5.82%)

ACB Aurora Cannabis
$1.27 /

-0.07 (-5.24%)

On The Fly
Rising High: Exclusive talk with cannabis testing firm Green Scientific » 11:49
06/09/22
06/09
11:49
06/09/22
11:49
ACB

Aurora Cannabis

$1.53 /

-0.04 (-2.56%)

, CVSI

CV Sciences

/

+

, CTST

CannTrust

/

+

, CGC

Canopy Growth

$3.95 /

-0.19 (-4.59%)

, CRON

Cronos Group

$2.80 /

-0.13 (-4.44%)

, CANN

General Cannabis

/

+

, GDNSF

Goodness Growth

$1.67 /

-0.09 (-5.11%)

, GTBIF

Green Thumb Industries

$11.35 /

+0.03 (+0.27%)

, IGC

India Globalization Capital

/

+

, TLRY

Tilray

$3.72 /

-0.19 (-4.86%)

, TCNNF

Trulieve Cannabis

$14.05 /

-0.38121 (-2.64%)

, ZYNE

Zynerba

$1.41 /

+0.4217 (+42.67%)

, ATAI

Atai Life Sciences

$3.44 /

-0.2 (-5.49%)

, CMPS

Compass Pathways

$9.84 /

-0.06 (-0.61%)

, RLMD

Relmada Therapeutics

$18.45 /

+0.03 (+0.16%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
$1.41 /

+0.4217 (+42.67%)

TLRY Tilray
$3.72 /

-0.19 (-4.86%)

TCNNF Trulieve Cannabis
$14.05 /

-0.38121 (-2.64%)

RLMD Relmada Therapeutics
$18.45 /

+0.03 (+0.16%)

GTBIF Green Thumb Industries
$11.35 /

+0.03 (+0.27%)

GDNSF Goodness Growth
$1.67 /

-0.09 (-5.11%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$2.80 /

-0.13 (-4.44%)

CMPS Compass Pathways
$9.84 /

-0.06 (-0.61%)

CGC Canopy Growth
$3.95 /

-0.19 (-4.59%)

ATAI Atai Life Sciences
$3.44 /

-0.2 (-5.49%)

ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

06/06/22 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
CVSI CV Sciences
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
CTST CannTrust
/

+

CGC Canopy Growth
$3.95 /

-0.19 (-4.59%)

06/08/22 BMO Capital
Canopy Growth downgraded to Underperform from Market Perform at BMO Capital
06/08/22 Barclays
Canopy Growth price target lowered to $3.50 from $6 at Barclays
05/31/22 Canaccord
Canopy Growth price target lowered to C$4.50 from C$6 at Canaccord
05/31/22 CIBC
Canopy Growth price target lowered to C$5 from C$6.50 at CIBC
CRON Cronos Group
$2.80 /

-0.13 (-4.44%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CANN General Cannabis
/

+

GDNSF Goodness Growth
$1.67 /

-0.09 (-5.11%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
GTBIF Green Thumb Industries
$11.35 /

+0.03 (+0.27%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
IGC India Globalization Capital
/

+

TLRY Tilray
$3.72 /

-0.19 (-4.86%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
TCNNF Trulieve Cannabis
$14.05 /

-0.38121 (-2.64%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
ZYNE Zynerba
$1.41 /

+0.4217 (+42.67%)

ATAI Atai Life Sciences
$3.44 /

-0.2 (-5.49%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
CMPS Compass Pathways
$9.84 /

-0.06 (-0.61%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$18.45 /

+0.03 (+0.16%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
ZYNE Zynerba
$1.41 /

+0.4217 (+42.67%)

TLRY Tilray
$3.72 /

-0.19 (-4.86%)

TCNNF Trulieve Cannabis
$14.05 /

-0.38121 (-2.64%)

RLMD Relmada Therapeutics
$18.45 /

+0.03 (+0.16%)

GTBIF Green Thumb Industries
$11.35 /

+0.03 (+0.27%)

CVSI CV Sciences
/

+

CRON Cronos Group
$2.80 /

-0.13 (-4.44%)

CMPS Compass Pathways
$9.84 /

-0.06 (-0.61%)

CGC Canopy Growth
$3.95 /

-0.19 (-4.59%)

ATAI Atai Life Sciences
$3.44 /

-0.2 (-5.49%)

ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

  • 27
    May
  • 09
    Dec
  • 18
    Jun
ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

CVSI CV Sciences
/

+

CGC Canopy Growth
$3.95 /

-0.19 (-4.59%)

ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

TLRY Tilray
$3.72 /

-0.19 (-4.86%)

CRON Cronos Group
$2.80 /

-0.13 (-4.44%)

CGC Canopy Growth
$3.95 /

-0.19 (-4.59%)

ATAI Atai Life Sciences
$3.44 /

-0.2 (-5.49%)

ACB Aurora Cannabis
$1.53 /

-0.04 (-2.56%)

On The Fly
Here's What You Missed in Cannabis This Week » 11:25
06/02/22
06/02
11:25
06/02/22
11:25
IIPR

Innovative Industrial Properties

$134.34 /

+1.23 (+0.92%)

, FLGC

Flora Growth

/

+

, RLMD

Relmada Therapeutics

$18.46 /

+0.45 (+2.50%)

, CMPS

Compass Pathways

$8.50 /

+0.03 (+0.35%)

, ATAI

Atai Life Sciences

$3.59 /

-0.06 (-1.64%)

, ZYNE

Zynerba

/

+

, TCNNF

Trulieve Cannabis

$14.27 /

-0.519479 (-3.51%)

, TLRY

Tilray

$4.41 /

+0.205 (+4.88%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$11.00 /

-0.2 (-1.79%)

, GDNSF

Goodness Growth

$1.58 /

-0.0082 (-0.52%)

, CANN

General Cannabis

/

+

, CRON

Cronos Group

$2.95 /

+0.085 (+2.97%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$1.63 /

+0.06 (+3.83%)

, INCR

InterCure

$6.41 /

+ (+0.00%)

, CGC

Canopy Growth

$4.71 /

+ (+0.00%)

, ETRGF

Entourage Health

/

+

, KHRNF

Khiron Life Sciences

/

+

In this week's "Rising…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TLRY Tilray
$4.41 /

+0.205 (+4.88%)

TCNNF Trulieve Cannabis
$14.27 /

-0.519479 (-3.51%)

RLMD Relmada Therapeutics
$18.46 /

+0.45 (+2.50%)

INCR InterCure
$6.41 /

+ (+0.00%)

IIPR Innovative Industrial Properties
$134.34 /

+1.23 (+0.92%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.00 /

-0.2 (-1.79%)

GDNSF Goodness Growth
$1.58 /

-0.0082 (-0.52%)

FLGC Flora Growth
/

+

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$2.95 /

+0.085 (+2.97%)

CMPS Compass Pathways
$8.50 /

+0.03 (+0.35%)

CGC Canopy Growth
$4.71 /

+ (+0.00%)

ATAI Atai Life Sciences
$3.59 /

-0.06 (-1.64%)

ACB Aurora Cannabis
$1.63 /

+0.06 (+3.83%)

IIPR Innovative Industrial Properties
$134.34 /

+1.23 (+0.92%)

06/02/22 JMP Securities
Innovative Industrial Properties price target lowered to $190 from $300 at JMP Securities
05/09/22 Craig-Hallum
Craig-Hallum upgrades Innovative Industrial Properties to Buy with $175 target
05/09/22 Craig-Hallum
Innovative Industrial Properties upgraded to Buy from Hold at Craig-Hallum
01/14/22 Piper Sandler
Innovative Industrial price target lowered to $285 from $290 at Piper Sandler
FLGC Flora Growth
/

+

10/13/21 Roth Capital
Flora Growth initiated with a Buy at Roth Capital
08/20/21 MKM Partners
Flora Growth price target raised to $11.50 from $6.00 at MKM Partners
06/23/21 MKM Partners
MKM Partners starts Flora Growth with Buy given its discount potential
06/22/21 MKM Partners
Flora Growth initiated with a Buy at MKM Partners
RLMD Relmada Therapeutics
$18.46 /

+0.45 (+2.50%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
CMPS Compass Pathways
$8.50 /

+0.03 (+0.35%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
ATAI Atai Life Sciences
$3.59 /

-0.06 (-1.64%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
ZYNE Zynerba
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
TCNNF Trulieve Cannabis
$14.27 /

-0.519479 (-3.51%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
TLRY Tilray
$4.41 /

+0.205 (+4.88%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.00 /

-0.2 (-1.79%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
GDNSF Goodness Growth
$1.58 /

-0.0082 (-0.52%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
CANN General Cannabis
/

+

CRON Cronos Group
$2.95 /

+0.085 (+2.97%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$1.63 /

+0.06 (+3.83%)

05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
INCR InterCure
$6.41 /

+ (+0.00%)

05/17/22 Canaccord
InterCure upgraded to Buy from Speculative Buy at Canaccord
CGC Canopy Growth
$4.71 /

+ (+0.00%)

05/31/22 Canaccord
Canopy Growth price target lowered to C$4.50 from C$6 at Canaccord
05/31/22 CIBC
Canopy Growth price target lowered to C$5 from C$6.50 at CIBC
05/31/22 Piper Sandler
Canopy Growth price target lowered to $4 from $6 at Piper Sandler
05/27/22 Alliance Global Partners
Canopy Growth price target lowered to C$7 from C$8 at Alliance Global Partners
ETRGF Entourage Health
/

+

06/02/22 Canaccord
Entourage Health downgraded to Hold from Speculative Buy at Canaccord
11/18/21 Canaccord
Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
11/17/21 Canaccord
Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord
KHRNF Khiron Life Sciences
/

+

ZYNE Zynerba
/

+

TLRY Tilray
$4.41 /

+0.205 (+4.88%)

TCNNF Trulieve Cannabis
$14.27 /

-0.519479 (-3.51%)

RLMD Relmada Therapeutics
$18.46 /

+0.45 (+2.50%)

INCR InterCure
$6.41 /

+ (+0.00%)

IIPR Innovative Industrial Properties
$134.34 /

+1.23 (+0.92%)

GTBIF Green Thumb Industries
$11.00 /

-0.2 (-1.79%)

FLGC Flora Growth
/

+

ETRGF Entourage Health
/

+

CVSI CV Sciences
/

+

CRON Cronos Group
$2.95 /

+0.085 (+2.97%)

CMPS Compass Pathways
$8.50 /

+0.03 (+0.35%)

CGC Canopy Growth
$4.71 /

+ (+0.00%)

ATAI Atai Life Sciences
$3.59 /

-0.06 (-1.64%)

ACB Aurora Cannabis
$1.63 /

+0.06 (+3.83%)

  • 27
    May
  • 01
    Apr
  • 09
    Dec
  • 19
    Nov
  • 18
    Jun
ZYNE Zynerba
/

+

IIPR Innovative Industrial Properties
$134.34 /

+1.23 (+0.92%)

RLMD Relmada Therapeutics
$18.46 /

+0.45 (+2.50%)

INCR InterCure
$6.41 /

+ (+0.00%)

IIPR Innovative Industrial Properties
$134.34 /

+1.23 (+0.92%)

FLGC Flora Growth
/

+

ETRGF Entourage Health
/

+

CGC Canopy Growth
$4.71 /

+ (+0.00%)

TLRY Tilray
$4.41 /

+0.205 (+4.88%)

CRON Cronos Group
$2.95 /

+0.085 (+2.97%)

CGC Canopy Growth
$4.71 /

+ (+0.00%)

ATAI Atai Life Sciences
$3.59 /

-0.06 (-1.64%)

ACB Aurora Cannabis
$1.63 /

+0.06 (+3.83%)

Hot Stocks
Zynerba presents data on Zygel as ASCP 2022 » 07:09
06/01/22
06/01
07:09
06/01/22
07:09
ZYNE

Zynerba

/

+

Zynerba Pharmaceuticals…

Zynerba Pharmaceuticals is presenting an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting, ASCP 2022, being held May 31 - June 3, 2022. The presentation titled, "Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome," includes data demonstrating that in the ongoing long-term safety and efficacy trial of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the greatest improvement in patients with complete methylation of their FMR1 gene. Patients with complete methylation, who match the primary efficacy population in the ongoing confirmatory trial, RECONNECT, achieved and maintained clinically meaningful change in Social Avoidance, supporting one of the key design enhancements for RECONNECT. Zygel was well-tolerated with long-term administration with up to 38 months of exposure. The poster titled, "RECONNECT: Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from CONNECT-FX Completed During SARS-COV-2 Pandemic," describes how learnings from CONNECT-FX, the first randomized, double-blind, placebo-controlled trial of Zygel in the treatment of FXS, shaped the design of RECONNECT. In addition to the primary endpoint of the RECONNECT trial being measured in patients who have a completely methylated FMR1 gene, the treatment period of the trial has been extended by four weeks and an additional weight-based dose has been added for participants weighing greater than 50kg.

ShowHide Related Items >><<
ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

Over a month ago
On The Fly
Rising High: Exclusive talk with cannabis company Tyson 2.0 » 11:42
05/26/22
05/26
11:42
05/26/22
11:42
CMPS

Compass Pathways

$7.97 /

+0.215 (+2.77%)

, ATAI

Atai Life Sciences

$4.01 /

+0.175 (+4.56%)

, RLMD

Relmada Therapeutics

$19.11 /

-0.08 (-0.42%)

, ZYNE

Zynerba

$1.01 /

+0.08 (+8.60%)

, TCNNF

Trulieve Cannabis

$14.12 /

-0.2871 (-1.99%)

, TLRY

Tilray

$4.63 /

+0.19 (+4.28%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$11.85 /

-0.24 (-1.99%)

, GDNSF

Goodness Growth

$1.53 /

+0.05 (+3.38%)

, CANN

General Cannabis

/

+

, CRON

Cronos Group

$3.13 /

+0.085 (+2.79%)

, CGC

Canopy Growth

$5.35 /

+0.315 (+6.26%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$2.75 /

+0.07 (+2.62%)

, CCHWF

Columbia Care

$2.03 /

+0.05 (+2.53%)

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
$1.01 /

+0.08 (+8.60%)

TLRY Tilray
$4.63 /

+0.19 (+4.28%)

TCNNF Trulieve Cannabis
$14.12 /

-0.2871 (-1.99%)

RLMD Relmada Therapeutics
$19.11 /

-0.08 (-0.42%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.85 /

-0.24 (-1.99%)

GDNSF Goodness Growth
$1.53 /

+0.05 (+3.38%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.13 /

+0.085 (+2.79%)

CMPS Compass Pathways
$7.97 /

+0.215 (+2.77%)

CGC Canopy Growth
$5.35 /

+0.315 (+6.26%)

CCHWF Columbia Care
$2.03 /

+0.05 (+2.53%)

ATAI Atai Life Sciences
$4.01 /

+0.175 (+4.56%)

ACB Aurora Cannabis
$2.75 /

+0.07 (+2.62%)

CMPS Compass Pathways
$7.97 /

+0.215 (+2.77%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
ATAI Atai Life Sciences
$4.01 /

+0.175 (+4.56%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
RLMD Relmada Therapeutics
$19.11 /

-0.08 (-0.42%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
ZYNE Zynerba
$1.01 /

+0.08 (+8.60%)

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
TCNNF Trulieve Cannabis
$14.12 /

-0.2871 (-1.99%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
TLRY Tilray
$4.63 /

+0.19 (+4.28%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.85 /

-0.24 (-1.99%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
GDNSF Goodness Growth
$1.53 /

+0.05 (+3.38%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
CANN General Cannabis
/

+

CRON Cronos Group
$3.13 /

+0.085 (+2.79%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CGC Canopy Growth
$5.35 /

+0.315 (+6.26%)

05/20/22 Alliance Global Partners
Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$2.75 /

+0.07 (+2.62%)

05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
CCHWF Columbia Care
$2.03 /

+0.05 (+2.53%)

05/18/22 Canaccord
Columbia Care price target lowered to C$4.50 from C$6 at Canaccord
05/16/22 Alliance Global Partners
Columbia Care price target lowered to C$8 from C$9 at Alliance Global Partners
03/24/22 Stifel
Cresco Labs downgraded to Hold from Buy at Stifel
02/07/22 Alliance Global Partners
Cannabis operators in PA could see near-term impact to sales, says AGP
ZYNE Zynerba
$1.01 /

+0.08 (+8.60%)

TLRY Tilray
$4.63 /

+0.19 (+4.28%)

TCNNF Trulieve Cannabis
$14.12 /

-0.2871 (-1.99%)

RLMD Relmada Therapeutics
$19.11 /

-0.08 (-0.42%)

GTBIF Green Thumb Industries
$11.85 /

-0.24 (-1.99%)

CVSI CV Sciences
/

+

CRON Cronos Group
$3.13 /

+0.085 (+2.79%)

CMPS Compass Pathways
$7.97 /

+0.215 (+2.77%)

CGC Canopy Growth
$5.35 /

+0.315 (+6.26%)

ATAI Atai Life Sciences
$4.01 /

+0.175 (+4.56%)

ACB Aurora Cannabis
$2.75 /

+0.07 (+2.62%)

  • 09
    Dec
  • 18
    Jun
ZYNE Zynerba
$1.01 /

+0.08 (+8.60%)

CRON Cronos Group
$3.13 /

+0.085 (+2.79%)

CMPS Compass Pathways
$7.97 /

+0.215 (+2.77%)

CGC Canopy Growth
$5.35 /

+0.315 (+6.26%)

CCHWF Columbia Care
$2.03 /

+0.05 (+2.53%)

TLRY Tilray
$4.63 /

+0.19 (+4.28%)

CRON Cronos Group
$3.13 /

+0.085 (+2.79%)

CGC Canopy Growth
$5.35 /

+0.315 (+6.26%)

ATAI Atai Life Sciences
$4.01 /

+0.175 (+4.56%)

ACB Aurora Cannabis
$2.75 /

+0.07 (+2.62%)

On The Fly
Rising High: Exclusive talk with biotech company Tryp Therapeutics » 11:59
05/19/22
05/19
11:59
05/19/22
11:59
GDNSF

Goodness Growth

$1.42 /

-0.05 (-3.40%)

, ZYNE

Zynerba

/

+

, TCNNF

Trulieve Cannabis

$14.37 /

-0.135 (-0.93%)

, TLRY

Tilray

$4.94 /

+0.15 (+3.13%)

, IGC

India Globalization Capital

/

+

, GTBIF

Green Thumb Industries

$11.67 /

-0.52 (-4.27%)

, CANN

General Cannabis

/

+

, CRON

Cronos Group

$3.48 /

+0.155 (+4.66%)

, CGC

Canopy Growth

$5.89 /

+0.3 (+5.37%)

, CTST

CannTrust

/

+

, CVSI

CV Sciences

/

+

, ACB

Aurora Cannabis

$3.08 /

+0.175 (+6.02%)

, RLMD

Relmada Therapeutics

$21.30 /

-0.3 (-1.39%)

, CMPS

Compass Pathways

$8.59 /

+0.36 (+4.37%)

, ATAI

Atai Life Sciences

$4.07 /

+0.125 (+3.17%)

, TRYPF

Tryp Therapeutics

/

+

In this edition of…

ShowHide Related Items >><<
ZYNE Zynerba
/

+

TRYPF Tryp Therapeutics
/

+

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

CVSI CV Sciences
/

+

CTST CannTrust
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

05/12/22 Canaccord
Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord
04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
02/01/22 Craig-Hallum
Goodness Growth downgraded to Hold from Buy at Craig-Hallum
11/11/21 Canaccord
Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord
ZYNE Zynerba
/

+

06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

05/12/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners
03/31/22 Canaccord
Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord
03/30/22 Alliance Global Partners
Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners
TLRY Tilray
$4.94 /

+0.15 (+3.13%)

05/02/22 Alliance Global Partners
Tilray price target lowered to $5.50 from $8 at Alliance Global Partners
04/20/22 Barclays
Tilray price target lowered to $4.50 from $8.50 at Barclays
04/06/22 MKM Partners
Tilray margins contracted despite cost savings, says MKM Partners
04/06/22 Benchmark
Tilray fiscal Q3 results 'disappointing,' says Benchmark
IGC India Globalization Capital
/

+

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

05/05/22 Alliance Global Partners
Green Thumb price target lowered to C$38 from C$40 at Alliance Global
05/05/22 Craig-Hallum
Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum
05/05/22 Needham
Green Thumb Industries price target lowered to $26 from $33 at Needham
CANN General Cannabis
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

05/11/22 CIBC
CIBC upgrades Cronos to buy on 'multiple reasons for optimism'
05/11/22 Canaccord
Cronos upgraded to Hold on operational improvements at Canaccord
05/11/22 CIBC
Cronos Group upgraded to Outperformer from Neutral at CIBC
05/11/22 Canaccord
Cronos Group upgraded to Hold from Sell at Canaccord
CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

05/20/22 Alliance Global Partners
Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners
04/04/22 Morgan Stanley
Constellation Brands price target lowered to $294 from $299 at Morgan Stanley
03/22/22 Barclays
Canopy Growth downgraded to Underweight from Equal Weight at Barclays
CTST CannTrust
/

+

CVSI CV Sciences
/

+

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

05/16/22 CIBC
Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
05/13/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
02/11/22 Cantor Fitzgerald
Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald
RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

05/09/22 Oppenheimer
Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer
12/20/21 SVB Leerink
Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink
11/17/21 Mizuho
Relmada Therapeutics initiated with a Buy at Mizuho
09/30/21 Jefferies
Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study
CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

05/17/22 Citi
Atai Life Sciences price target lowered to $22 from $26 at Citi
04/01/22 Canaccord
Atai Life Sciences price target lowered to $27 from $28 at Canaccord
03/31/22 RBC Capital
Atai Life Sciences price target lowered to $9 from $12 at RBC Capital
11/30/21
Fly Intel: Top five analyst initiations
TRYPF Tryp Therapeutics
/

+

08/26/21 Ladenburg
Tryp Therapeutics initiated with a Buy at Ladenburg
ZYNE Zynerba
/

+

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

TCNNF Trulieve Cannabis
$14.37 /

-0.135 (-0.93%)

RLMD Relmada Therapeutics
$21.30 /

-0.3 (-1.39%)

GTBIF Green Thumb Industries
$11.67 /

-0.52 (-4.27%)

CVSI CV Sciences
/

+

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CMPS Compass Pathways
$8.59 /

+0.36 (+4.37%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

  • 09
    Dec
  • 18
    Jun
GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

GDNSF Goodness Growth
$1.42 /

-0.05 (-3.40%)

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

TLRY Tilray
$4.94 /

+0.15 (+3.13%)

CRON Cronos Group
$3.48 /

+0.155 (+4.66%)

CGC Canopy Growth
$5.89 /

+0.3 (+5.37%)

ATAI Atai Life Sciences
$4.07 /

+0.125 (+3.17%)

ACB Aurora Cannabis
$3.08 /

+0.175 (+6.02%)

Syndicate
Zynerba files $300M mixed securities shelf  07:59
05/16/22
05/16
07:59
05/16/22
07:59
ZYNE

Zynerba

/

+

 
ShowHide Related Items >><<
ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

04/01/22 Alliance Global Partners
Senate remains the hurdle for MORE Act, says Alliance Global Partners
06/25/21 Alliance Global Partners
Cannabis selloff brings buying opportunities, says Alliance Global
ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

ZYNE Zynerba
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.